Table 1.

Clinical signs observed following α-CSPG4 rIgE, MOv18 rIgE or PBS administration.

	PBSa (n = 4)	MOv18 rIgEa (n = 4)	α-CSPG4 rIgEa (n = 4)	α-CSPG4 rIgEb (n = 3)
Drinking	Normal	Normal	Abnormal behaviour	Abnormal behaviour
Piloerection	Normal	Mild	Moderate	Moderate
Responsiveness	Normal	Normal-Mild	Moderate	Moderate
Peer interaction	Normal	Normal	Moderate	Moderate
Hunching	Normal	Normal	Mild	Mild
Vocalisation	Normal	Normal	Normal	Normal
Oculo-nasal discharge	Normal	Normal	Normal	Normal
Respiration	Normal	Normal	Moderate	Moderate
Tremors	Normal	Normal	Normal	Normal
Convulsions	Normal	Normal	Normal	Normal
Prostration	Normal	Normal	Moderate	Moderate
Self-mutilation	Normal	Normal	Normal	Normal

^aCC531-hCSPG4 cells injected via tail vein 24 hours before antibody administration.

^bCC531 cells injected via tail vein 24 hours before antibody administration.